Cargando…

Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody

Hepatocellular carcinoma (HCC) is an aggressive liver tumor that occurs due to chronic liver disease, and it has a high mortality rate and limited treatment options. Immune checkpoint inhibitors have been successfully introduced and used in cancer therapy, among which inhibitors of programmed death...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Gang, Zhou, Wenxuan, Li, Xiaoli, Guo, Lijie, He, Tingting, Zhao, Juan, Gong, Liansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422947/
https://www.ncbi.nlm.nih.gov/pubmed/34504494
http://dx.doi.org/10.3389/fimmu.2021.712351
_version_ 1783749375294439424
author Liu, Gang
Zhou, Wenxuan
Li, Xiaoli
Guo, Lijie
He, Tingting
Zhao, Juan
Gong, Liansheng
author_facet Liu, Gang
Zhou, Wenxuan
Li, Xiaoli
Guo, Lijie
He, Tingting
Zhao, Juan
Gong, Liansheng
author_sort Liu, Gang
collection PubMed
description Hepatocellular carcinoma (HCC) is an aggressive liver tumor that occurs due to chronic liver disease, and it has a high mortality rate and limited treatment options. Immune checkpoint inhibitors have been successfully introduced and used in cancer therapy, among which inhibitors of programmed death ligand-1 (PD-L1) and its receptor programmed death-1 (PD-1) are commonly administered for HCC as combination therapy, including combined anti-angiogenic and immunotherapy combination therapy. We report a case of a primary massive HCC patient with portal hepatic vein tumor thrombus who had a good response to atezolizumab in combination with bevacizumab, following progression of disease on combined immunotherapy with pembrolizumab and lenvatinib. This case demonstrates for the first time that an HCC patient who is resistant to anti-PD-1 antibody immunotherapy can benefit from anti-PD-L1 antibody immunotherapy, providing a potentially promising strategy for the treatment of HCC.
format Online
Article
Text
id pubmed-8422947
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84229472021-09-08 Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody Liu, Gang Zhou, Wenxuan Li, Xiaoli Guo, Lijie He, Tingting Zhao, Juan Gong, Liansheng Front Immunol Immunology Hepatocellular carcinoma (HCC) is an aggressive liver tumor that occurs due to chronic liver disease, and it has a high mortality rate and limited treatment options. Immune checkpoint inhibitors have been successfully introduced and used in cancer therapy, among which inhibitors of programmed death ligand-1 (PD-L1) and its receptor programmed death-1 (PD-1) are commonly administered for HCC as combination therapy, including combined anti-angiogenic and immunotherapy combination therapy. We report a case of a primary massive HCC patient with portal hepatic vein tumor thrombus who had a good response to atezolizumab in combination with bevacizumab, following progression of disease on combined immunotherapy with pembrolizumab and lenvatinib. This case demonstrates for the first time that an HCC patient who is resistant to anti-PD-1 antibody immunotherapy can benefit from anti-PD-L1 antibody immunotherapy, providing a potentially promising strategy for the treatment of HCC. Frontiers Media S.A. 2021-08-24 /pmc/articles/PMC8422947/ /pubmed/34504494 http://dx.doi.org/10.3389/fimmu.2021.712351 Text en Copyright © 2021 Liu, Zhou, Li, Guo, He, Zhao and Gong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Liu, Gang
Zhou, Wenxuan
Li, Xiaoli
Guo, Lijie
He, Tingting
Zhao, Juan
Gong, Liansheng
Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
title Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
title_full Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
title_fullStr Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
title_full_unstemmed Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
title_short Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
title_sort case report: complete response of primary massive hepatocellular carcinoma to anti-programmed death ligand-1 antibody following progression on anti-programmed death-1 antibody
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422947/
https://www.ncbi.nlm.nih.gov/pubmed/34504494
http://dx.doi.org/10.3389/fimmu.2021.712351
work_keys_str_mv AT liugang casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody
AT zhouwenxuan casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody
AT lixiaoli casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody
AT guolijie casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody
AT hetingting casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody
AT zhaojuan casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody
AT gongliansheng casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody